GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galapagos NV (LTS:0JXZ) » Definitions » Short Percentage of Float

Galapagos NV (LTS:0JXZ) Short Percentage of Float


View and export this data going back to . Start your Free Trial

What is Galapagos NV Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Galapagos NV's Short Percentage of Float

For the Biotechnology subindustry, Galapagos NV's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Galapagos NV's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Galapagos NV's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Galapagos NV's Short Percentage of Float falls into.


Galapagos NV (LTS:0JXZ) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galapagos NV (LTS:0JXZ) » Definitions » Short Percentage of Float
Comparable Companies
XAMS:PHARM XAMS:BAI XAMS:VVY OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB XBRU:ARGX BNTX OCSE:GMAB ALNY BGNE BMRN RPRX SRPT SHSE:603392
Traded in Other Exchanges
GLPG:USA GLPG:Netherlands GLPG:Mexico GXE:Germany GXE:Germany G1LP34:Brazil GLPG:Austria
Address
Generaal De Wittelaan L11 A3, Mechelen, BEL, 2800
Website
https://www.glpg.com
Galapagos NV is a clinical-stage biotechnology company, involved in the discovery and development of small-molecule medicines. The company's product candidate portfolio includes Filgotinib, a JAK1 inhibitor to treat rheumatoid arthritis, Crohn's disease, and ulcerative colitis; novel therapies in cystic fibrosis (a chronic disease that affects the lungs and digestive system); GLPG1690, a selective autotaxin inhibitor with potential application in idiopathic pulmonary disease; GLPG1972 to treat osteoarthritis; and MOR106 to treat atopic dermatitis.

Galapagos NV (LTS:0JXZ) Headlines

No Headlines